Effects of PKC412, Nilotinib, and Imatinib Against GIST-Associated PDGFRA Mutants With Differential Imatinib Sensitivity
Open Access
- 31 December 2006
- journal article
- Published by Elsevier in Gastroenterology
- Vol. 131 (6), 1734-1742
- https://doi.org/10.1053/j.gastro.2006.09.017
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumoursEuropean Journal Of Cancer, 2006
- PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effectsBlood, 2006
- Pathology of gastrointestinal stromal tumorsPathology International, 2006
- PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to ImatinibJournal of Clinical Oncology, 2005
- Characterization of AMN107, a selective inhibitor of native and mutant Bcr-AblCancer Cell, 2005
- Different inhibitory effect of imatinib on phosphorylation of mitogen‐activated protein kinase and Akt and on proliferation in cells expressing different types of mutant platelet‐derived growth factor receptor‐αInternational Journal of Cancer, 2004
- The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA–positive chronic eosinophilic leukemiaBlood, 2004
- Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal TumorJournal of Clinical Oncology, 2003
- Inhibition of FLT3 in MLLCancer Cell, 2003
- PDGFRA Activating Mutations in Gastrointestinal Stromal TumorsScience, 2003